Study: NCT02846506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.